Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have suggested activity of other analogues. In two studies...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nielsen, Ole S., Dombernowsky, Per, Mouridsen, Henning, Daugaard, Søren, Van Glabbeke, Martine, Kirkpatrick, Anne, Verweij, Jaap
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2000
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2408358/
https://ncbi.nlm.nih.gov/pubmed/18521432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/S1357714X00000062
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak